✉news HealthMental Health first seen 16 h ago, last 5 h ago, peak #37
First Patient Dosed in Phase 2a Trial of GlyphAgo for Anxiety
Original: First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
The first patient has been dosed in a Phase 2a clinical trial of GlyphAgo, an investigational treatment for generalized anxiety disorder and sleep disturbance. The announcement marks the start of patient enrollment in the mid-stage study, a key step in testing whether the drug can safely and effectively address both anxiety and related sleep problems.
Why now: Clinical trial milestones for new anxiety treatments draw attention amid growing demand for mental health therapies.
Rank over time, top of the chart is #1. 9 snapshots from 16 h ago to 5 h ago.
Evidence
- First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance · Psychiatric Times
API: https://socialmediatrends-api.osmike.com/v1/trends/1380863